Avadel Pharmaceuticals PLC (AVDL)

Avadel Pharmaceuticals PLC (AVDL) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Feb 11, 2026: market cap $2.1B; returns 1 week +0.4%, 1 year +140.6%.

Avadel Pharmaceuticals PLC is a commercial-stage biopharmaceutical company primarily focused on the development and commercialization of LUMRYZ, a once-nightly formulation of sodium oxybate. LUMRYZ is the first and only FDA-approved extended-release oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

AVDL financial model: income statement, cash flow and balance sheet